Ipilimumab Induced Enterocolitis: A Fatal Immune-Related Adverse Event of Melanoma Treatment

Chandamuri Babi, Spiegel Jaclyn, Nicaud Mark, Hutchings John


Ipilimumab is a human monoclonal antibody that has recently been approved for treatment of stage III or IV melanoma. Although it is has proven to be a generally safe drug, treatment with ipilimumab has been associated with potentially fatal adverse effects. We present a fatal case of enterocolitis caused by just one cycle of ipilimumab therapy.


Ipilimumab, Diarrhea, Enterocolitis, Melanoma, Immune, Adverse

Full Text: PDF HTML


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.